Who’s guilty of “clickbait”? Are spit tubes a bad business? And why are academics emulating Pusha T?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we discuss Novartis’ decision to charge $2.1 million for its gene therapy — and the backlash to news organizations pointing that out. Then, Bloomberg reporter Kristen Brown joins us to discuss how companies are struggling to make money in the world of consumer genetic testing. Finally, we delve into a scandal at MIT that finds one professor accusing another of academic malfeasance.
For more on what we cover, here’s the Novartis news; here’s the latest on consumer genetics; and here’s more on the MIT situation.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
